Anzeige
Mehr »
Login
Mittwoch, 22.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Kursexplosion von 383 % seit November und massiver Solana-Outperformer!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A2AH4C | ISIN: CA58600T1084 | Ticker-Symbol: 1M6
Branche
Software
Aktienmarkt
Sonstige
1-Jahres-Chart
MEMEX INC Chart 1 Jahr
5-Tage-Chart
MEMEX INC 5-Tage-Chart
ACCESS Newswire
521 Leser
Artikel bewerten:
(2)

Memex Inc.: Memex Extends Loan Facility Arrangements With Its Secured Lenders

Finanznachrichten News

BURLINGTON, ON / ACCESSWIRE / March 27, 2024 / Memex Inc. ("Memex" or the "Company") (TSXV:OEE), a leader in Industrial Internet of Things (IIoT) manufacturing productivity software, today announced that it has finalized nineteen (19) month loan facility extension arrangements with its secured lenders in conjunction with Officers of Memex (collectively the "Lenders"), on the remaining $209 thousand (the "Loan") balance (secured lenders - $195 thousand, Officers of Memex - $14 thousand). Previously scheduled to mature on March 31, 2024, these arrangements extend the maturity date to October 31, 2025, with the same repayment terms, and no changes to the effective interest rates or security arrangements. No refinancing fee or other incentives were provided to the Lenders for their agreement to extend the maturity of the loan.

Status update on FFCTO - The Company including its' auditors, are continuing to work to complete the annual financial statements for Memex's year ended September 30, 2023, including the related management discussion and analysis, and CEO and CFO certifications (collectively, the "Annual Financial Filings"). The Company's management and Directors are working towards being in a position to file its Annual Financial Filings before April 27, 2024.

As previously reported, the Ontario Securities Commission (OSC) issued a Failure-to-file Cease Trade Order (a "FFCTO") in respect of the securities of Memex effective February 2, 2024 for its failure to file its Annual Financial Filings by the filing deadline of January 28, 2024 (the "Filing Deadline"). The delay in filing the Annual Financial Filings was due to the Company's inability to commence audit procedures in a timely manner due to financial constraints. The FFCTO issued by the OSC also affected each jurisdiction of Canada that has a statutory reciprocal order provision. Further, as a result of the FFCTO, the TSX Venture Exchange suspended trading in the Company's shares.

Until the Annual Financial Filings are filed, the Company intends to continue to issue bi-weekly default status reports. The Company confirms that there is no other material information relating to its affairs that has not been generally disclosed.

About Memex Inc.:

Established in 1992, Memex grew to be an industry leader in Industry Internet of Things (IIoT) through the development of MERLIN Tempus, an award-winning platform that delivers real-time, tangible increases in manufacturing productivity. Memex is on the leading edge of industry trends in computing power, machine connectivity, industry standards, advanced software technology, and manufacturing domain expertise.

Our persistent pursuit of innovative IIoT solutions led to a comprehensive understanding of the challenge's manufacturers face. We made it our mission to, "successfully transform factories of today into factories of the future." As the global leader in Machine to Machine (M2M) connectivity solutions, our hardware and software products create unparalleled visibility at all levels, from "Shop-Floor-to-Top-Floor."

The MERLIN Tempus Suite provides effective quantification and management of Overall Equipment Effectiveness (OEE) by revealing hidden capacity using real-time objective data. Further, it offers sustainable benefits that enable world-class OEE such as reducing costs, incorporating strategies for continuous LEAN improvement, and boosting bottom-line financial performance. For more information, please visit: www.MemexOEE.com

For investor inquiries please contact:

Ed Crymble, Chief Financial Officer
905-635-1540
investor.relations@memexOEE.com

David McPhail, President & CEO
905-635-1540
investor.relations@memexOEE.com

Neither the TSX Venture Exchange nor its Regulation services provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

_________________________________

SOURCE: Memex Inc.



View the original press release on accesswire.com

© 2024 ACCESS Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.